Synergistic Effects of Combined PROTAC-based EZH2 Degrader and METTL3 Inhibitor in Burkitt’s Lymphoma
Open Access
- 30 September 2024
- journal article
- Published by The Korean Society for Clinical Laboratory Science in Korean Journal of Clinical Laboratory Science
- Vol. 56 (3) , 198-206
Abstract
Minseo YU, Ra Eun KIM, Yurim JEONG, Hyewon JANG, Se Been KIM, Jung-Yeon LIM. Korean J Clin Lab Sci. 2024;56:198-206. https://doi.org/10.15324/kjcls.2024.56.3.198Keywords
Funding Information
- Inje University (20230017)
This publication has 30 references indexed in Scilit:
- Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2European Journal of Medicinal Chemistry, 2024
- Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniquesEuropean Journal of Medicinal Chemistry, 2023
- Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphomaBioorganic Chemistry, 2023
- Developing antibody-based PROTACsNature Reviews Drug Discovery, 2022
- Targeted Protein Degradation via LysosomesBiochemistry, 2022
- Structural basis of the p53 DNA binding domain and PUMA complexBiochemical and Biophysical Research Communications, 2021
- Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Journal of Medicinal Chemistry, 2021
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugsEBioMedicine, 2018
- Targeted protein degradation by PROTACsPharmacology & Therapeutics, 2017
- PUMA, a potent killer with or without p53Oncogene, 2008